Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis

• Conditions: Autoimmune Encephalitis; Anti NMDA Receptor Encephalitis; Herpetic Encephalitis
• Interventions: Other: Description and analysis

• Registration Number: NCT04339127
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Herpes Simplex Virus encephalitis is the most common infectious encephalitis, with an estimated annual incidence of 1 / 250,000 to 1 / 500,000 in industrialized countries. Despite a widely used antiviral treatment, the prognosis remains poor with a mortality of 5 to 20% and a considerable morbidity rate.

One of the contributing factors of bad prognosis is the development of encephalitis mediated by autoantibodies, most often directed against NMDA receptors, in the weeks following viral encephalitis.

The description of this pathology is recent, the pathophysiology of this process remains poorly understood, and the management of these patients is not yet codified.

Detailed Description

Not available

Study Timeline

• Status Verified: 2020-04
• Study Start: 2020-04-01
• Study First Submitted: 2020-04-06
• Study First Submitted QC: 2020-04-06
• Last Update Submitted: 2020-04-06
• Study First Posted: 2020-04-09
• Last Update Posted: 2020-04-09
• Primary Completion: 2020-06-01
• Study Completion: 2020-10-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• Clinical autoimmune encephalitis with anti-NMDA antibodies and documented by CBA in the CSF
• After a herpetic encephalitis documented by a positive viral PCR for HSV in the CSF
• Without age limit

Exclusion Criteria- No respect of inclusion criteria

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Cohort NMDARE-HSE	Description and analysis	Patients developing clinical autoimmune encephalitis with anti-NMDA antibodies after a herpetic encephalitis, managed by the National Reference Center for Paraneoplastic Syndromes and Autoimmune Encephalitis at the Neurological Hospital of Bron.

Primary Outcome Measures

Name	Time	Method
Details of clinical, biological, imaging, therapeutic characteristics and patient's evolution.	at 6 and 12 months	Retrospective collection of clinical, diagnostic and therapeutic data, evolution at 6 and 12 months.

Trial Locations

Locations (1)

Hospice Civils de Lyon; 🇫🇷 Bron, France